Shield Therapeutics Share Discussion Threads

[best1467] 08/1/2020 07:41

Guess I will not be adding but great deal $11 million upfront with a great tiered royalty rate and they are covering the trail development costs.
On that basis if we add on the development and p3 trail costs onto the $11 million plus a little extra for the USA market that will be the range for the upfront on the US deal

[nobbygnome] 08/1/2020 07:37

Yes who was it yesterday saying they were pulling our capital? Extremely bad timing and inexplicable. Too many nervous nellies as I said yesterday....

[peachie 74] 08/1/2020 07:35

Fantastic news.
What a major step forward.
Hope the recent sellers don’t get too badly burnt here

[deeppockets] 08/1/2020 07:08

Looks like a great deal and so surely US is round the corner

[nobbygnome] 08/1/2020 07:08

Yes great to see the licensing deal for China signed. The most important aspect is that the upfront means that cash is now not an issue. The longer the US deal went without being signed, the closer we were getting to the company running out of cash resources (3rd quarter this year) which must have put Shield in a weaker position in negotiations. Plus the further cash to come with the milestones which are highly likely to be met in the relatively near future gives them good visibility on cash going forward.

Onwards and upwards

[growthinvestor2001] 08/1/2020 07:01

China deal announced - got news in chinese but might be wrong

[siriusbizness] 07/1/2020 19:41

My only other concern is the sales with Norgine in Europe. Update due soon so we shall see. The head to head study was good. I don’t think there would be any manufacturing issues. On the other hand it could be selling amazingly and giving the board confidence to seek a better deal

[norfolk enchance] 07/1/2020 18:25

My only real concern at the moment with this company and possibly holding the share price back, is the Legal proceedings hanging over them re. the Teva appeal of the Ferracru patent to which a date still hasn't been set and no update since June - never seems to get a mention on here. Is it being ignored or forgotten? What are people's views on it?

[crankyman] 07/1/2020 17:35

If Norgine have managed to get some traction especially in Germany that could counter that and set up a strong growth story for the US

[crankyman] 07/1/2020 17:33

Just on the point of the price compared to the list price, that’s correct but it did drift down to around £1 just before the CKD study and it is now approaching double that. As for where it goes, the only fundamental change will be the upfront. The argument will remain that it is not yet generating incomes beyond that so the true trajectory of revenues is not known so it can’t be priced.

[best1467] 07/1/2020 16:55

Don’t like to comment about personal trading on this thread or any other but will be looking to add on any further weakness .
What are we now 25pence above listing valuation which is crazy with what’s been achieved but it’s all about opinion at the end of the day so let’s see how it plays out

[nobbygnome] 07/1/2020 16:52

And what 2theduke says is correct, the volumes are very low. I make it that 0.05% of the shares were traded today...

[nobbygnome] 07/1/2020 16:46

A lot of nervous nellies here which sums up the market these days. Carl Sterrit always said he wouldn't rule out taking the discussions past year end to get the right deal. We all want the deal announced ASAP but it is just a question of patience as a deal will most definitely come. As I keep on saying STX cannot sell the drug themselves in the US so a deal is ineveitable.

I continue to pick up small parcels of shares as the price drifts down. It is an open goal to me especially at the current levels.

[2theduke] 07/1/2020 11:49

Just FYI guys: the small falls off small volume is just me taking some capital out after the discussions. Liquidy is super thin so hence this small drift.

[montyhedge] 06/1/2020 12:37

Every thing virtually closed down for two weeks Christmas and new year. Corporate departments.Now everyone back, I reckon news within weeks.

[crankyman] 06/1/2020 09:31

No NICE or SMC opinion doesn’t help

[borromini1] 06/1/2020 09:19

2TD - I did not find the actual review comments, I assume they are not made public.

Just seems odd that the global reference for clinical trials still has NO RESULTS published a full TEN MONTHS after STX issued their announcement RNS on the head to head study on 4 March 2019 with Carl Sterritt, CEO boasting ...

"We look forward to presentations of the AEGIS-H2H data at upcoming scientific meetings and working with our commercial partners to ensure prescribers, payors, experts responsible for the publication of treatment guidelines and the many eligible patients are aware that Feraccru® offers a simple to administer, well tolerated and efficacious oral treatment alternative to IV iron therapy, without the need for hospital-based administration."

I also can not find ANY UK NHS Area Prescribing Committee making any reference to the head to head study results in published documents and Feraccru prescribing guidance. Only a footnote reference link to the trial on clinicaltrials.gov

I can find two staff vacancies at Norgine for key regulatory roles unfilled since last Aug/Sept.

[2theduke] 05/1/2020 21:33

Bromin could you find the review comments ? I went to the site but could not find them - do you have amore direct link?

Separately. Can anyone think why there has been no management update on the process given the prior mentions of q3 and q4 (or indeed “as soon as possible after fda approval” ) comments. I’m struggling to think why management would not issue a statement saying discussions continues.

[nobbygnome] 05/1/2020 18:57

>> borromini1

Short answer, no!

[best1467] 05/1/2020 16:28

Patience is key I don’t see not getting a deal done by year end as a negative on the basis if they had narrowed it down to say two potential partners quite quickly a deal could well of happened.
My gut feeling with the broad label approval the interest was greater and on that basis more interested parties taking longer to negotiate and the likelihood of a fruitful deal or even a takeover approach from a interested party.

[borromini1] 05/1/2020 16:26

What is this about ...

Results Returned after Quality Control Review
December 12, 2019



The date on which the National Library of Medicine provided quality control (QC) review comments to the study sponsor or investigator. The sponsor or investigator must address major issues identified in the review comments. If there is a date listed for results returned after quality control review, but there is not a subsequent date listed for results submitted to ClinicalTrials.gov, this means that the submission is pending changes by the sponsor or investigator.

Could the delay in STX getting the head to head study results accepted and published on the above US governmental web site be slowing down the Feraccru/Accrufer deal finalisation or even UK regulatory reviews?

[borromini1] 05/1/2020 12:12

NYB - European Patent Office, Teva patent challenge ... so STX responded on the last day of the standard 4 month reply period, the composition of the Appeal Panel was set in early December, did you gain any insight as to how long before the panel formally address the case and typical time scales for delivery of judgement?

Last July our friends at Edison marked down STX by 35 percent of their base case (82p per share) to give a valuation of 273 million GBP thereby reflecting their perceived risk to the patent. The converse being they will increase their base case figure by 50 percent if the patent challenge fails. That, according to Edison, is another significant potential uplift event bubbling away in the background.

[crankyman] 03/1/2020 22:12

I think the deal will come. It has to. I assume they will be in JP Morgan mid January so that’s the next timeline for getting it done.